Imprime PGG: Interim Phase I/II data

Interim data from 11 evaluable patients enrolled in an open-label, U.S. Phase I/II trial showed that once-weekly 1, 2 and 4 mg/kg Imprime PGG in combination with rituximab and alemtuzumab produced 7 complete responses and 4 partial responses. There were no dose-limiting toxicities (DLTs). There was 1 case of grade 4 febrile neutropenia. The trial is scheduled to enroll a total of 55 patients. Data were presented at the American Society of Hematology meeting in Atlanta. ...